Not a single study
Story checked
Joe Rogan Experience #371 — Rick Doblin Transcript | JRE Database (opens in a new tab)
joeroganpodcast.org · 2013-07-01
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Joe Rogan Experience #371 — Rick Doblin Transcript | JRE Database
joeroganpodcast.org · 2013-07-01
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 8Not checkedDoblin says his current study is on MDMA for post-traumatic stress disorder.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 8Not checkedHe says PTSD treatment in the study includes only three days of MDMA and a treatment manual describing the therapy component.View evidenceHide evidence
As statedthree days
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 8Not checkedDoblin says the MDMA/PTSD work is blocked politically and that marijuana research is the most politically blocked area right now.View evidenceHide evidence
As statedmost politically blocked right now
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 8Not checkedHe argues that marijuana could become an FDA-approved medicine in about five or six years.View evidenceHide evidence
As statedfive, six years
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 8Not checkedHe says phase II studies funded by the state of California showed that combining marijuana with opiates helped many people.View evidenceHide evidence
As statedmany people
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 8Not checkedHe says a psilocybin study in spiritually inclined people found the experiences to be uniformly positive, with many participants losing their fear of death and becoming more focused on the present.View evidenceHide evidence
As statednine out of the 20 people had either a partial or a full
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 8Not checkedHe describes discussion of combining LSD and MDMA in a staged way, with LSD first and MDMA several hours later.View evidenceHide evidence
As statedtwo hours... four hours later
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 8Not checkedDoblin says psychedelic medicines and therapy should be used to help people heal themselves and that people should be supported in exploring consciousness and ending prohibition.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref · 15 candidate papers
[The use of psychedelics in psychiatry].
Orvosi Hetilap · 2026 · PubMed
Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD
Journal of Psychoactive Drugs · 2019 · Crossref
MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis.
Harvard Review of Psychiatry · 2026 · PubMed
To what extent is MDMA-assisted psychotherapy helping individuals with treatment-resistant post-traumatic stress disorder (PTSD)?
Crossref
The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis.
Journal of Psychopharmacology (Oxford, England) · 2026 · PubMed
And 10 more candidates considered.